An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

PHASE IIA TRIAL EVALUATING THE SAFETY AND THERAPEUTIC EFFECT OF INTRAPLEURAL IMPLANTATION OF SMS001 AS AN ADJUVANT THERAPY TO CONTROL LYMPHATIC METASTASIS IN STAGE IA-IIIA (N2) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS UNDERGOING CANCER SURGERY

Intervention/treatment:
PACLITAXEL (SMS001)
Medical condition:
NON-SMALL CELL LUNG CANCER
Protocol code:
132551-1
Control number:
276843
Status:
Recruiting
Approved:
September 01, 2023
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06693336
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Jennifer Lister / Clinical Research Coordinator / UHN
Role
CONTACT
Phone:
1-416-340-4857
Sponsor
TOLYMPH INC.

Locations

Ontario

Toronto General Hospital
Toronto, Ontario, M5G 2C4
RECRUITING
Name
Kazuhiro Yasufuku / Principle Investigator
Role
CONTACT
Phone:
416-340-4798
Did you find what you were looking for?